Do you have chronic lymphocytic leukemia and have not received a previous treatment for your cancer? You may be able to take part in a new research study comparing treatments for Chronic Lymphocytic Leukemia.

This clinical trial will study a drug known as CAEL-101. CAEL-101 is a monoclonal antibody. The purpose of the study is to learn if CAEL-101 helps people with AL amyloidosis that has affected their hearts to live longer.

This is a research study to learn if a new experimental drug when given with standard of care is safe and effective as a treatment for men with metastatic hormone-sensitive prostate cancer (mHSPC). The drugs that are part of this study are Docetaxel and Radium-223.

Have you been diagnosed with bladder cancer? You may be able to take part in a research study looking at a combination of chemotherapy drugs given with immunotherapy for patients with muscle invasive bladder cancer.

Are you experiencing symptoms of menopause? Have you noticed a change in your mood during your menopausal transition? If you have missed at least two periods, you may be able to take part in a research study. In this study, we want to learn how mood and stress may affect risk for heart disease in women during menopause.

The purpose of the study is to learn if the study drug (CAEL-101) helps people with AL amyloidosis that has affected their hearts to live longer. CAEL-101 is a monoclonal antibody, which is made to bind to specific things in your body like the proteins that cause AL amyloidosis

If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

In this study, we want to learn more about the impact on progression-free survival (PFS) for patients with multiple myeloma when taking a combination of four drugs. The four drugs in this study are lenalidomide, ixazomib, dexamethasone, and daratumumab.

Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.